ILYA Pharma

Why are there no #therapeutics today based on #chemokines and similar #immunoactive proteins capable of instructing immune cells locally in the body? Because of their biochemical properties and the importance of the spatial distribution for their function they are not optimal to develop as either biologics or classic gene therapy. We made a short video explaining how the ILP-technology can #unlock many immunoactive proteins for development as therapeutics - in a #cheap and #scalble way. #ILP100 #impact #clinicaldevelopment #genetherapy https://lnkd.in/eXR7-pHi

Our developments of #ILP100 #Oral was highlighted in an Editorial Focus 🧫 🧬 💊 💩 🔬 "The implications of this study are substantial, extending beyond immediate therapeutic benefits to broader impacts on the field of colitis treatment and potentially other inflammatory diseases. The methodology used in this study could be adapted for other inflammatory diseases by engineering L. reuteri to express different therapeutic proteins. This broadens the potential applications of this approach beyond colitis" Our asset ILP100-Oral is currently at IND stage in development with: ✅ #FDA pre-IND meeting completed allowing #first #line #treatment ✅ SITU-GUT clinical phase 1/2a trial developed with #KOLs for ICI-induced colitis stage 1 and 2 ✅CMC and GMP synergies with ILP100-Topical already in Phase 2 clinical developments with IND cleared for pivotal study ✅ Exceptional #COGs, #stability in #RT ✅ Projections of #blockbuster potential ➡️ We are looking for a #partner to accelerate the clinical development for this asset and share the #joys of developing ground breaking research 💊 and the expected #value generated💰 💰 Mia Phillipson Stefan Roos Zhanar Myktbektova Emelie Öhnstedt Ninus Caram-Lelham Peter Frank Margareth Jorvid Macarena del Pilar Carrasco López Cristian Doñas Yinhong Wang Patricia Grigoleit

Spot on describing the #problem - we are contributing to the #solution. Link to preprint of our data: https://lnkd.in/dMsbj25z #ILP100 #ILP101 #science #innovation #value #impact #MDR #AMR #pandemicpreparedness #nordicmade

ILYA Pharma will be in San Francisco next week for J.P. Morgan Health Care Conference. Our CEO Evelina Vågesjö will be there - reach out to learn about Ilyas lead program #ILP100 for #ultra #rare #pediatric #SAVI. #JPM2025 #FDA #RPDD #PRV #value #NIH

It is always #people who break new ground, innovate and validate. We wish you all nice holidays and look forward to next years opportunities.  #merrychristmas #recharge #getinspired #curious #determined #persistent Mia Phillipson Stefan Roos Hava Lofton Tomenius Ninus Caram-Lelham Hava Lofton Tomenius Anna Hill Margareth Jorvid Emma Gyllenpalm Yanhong Pang Sandeep Kadekar Macarena del Pilar Carrasco López Peter Frank Zhanar Myktybktova

Ilya Pharma accepted to great program preparing European Scale ups for US partnerships, product launch and approaching US investors for the first time. This year is a great cohort of 6 companies getting premium support to shape up, scale up and master multiple markets and business cultures. Thanks #GSP, Health~Holland, Marianne van der Steen Ph.D. for also extending the invitation to one company from #Sweden 💊 🩸 💰 🧫 🧬 Link to the program: https://lnkd.in/dVY4Ed-q

Welcome Giacomo Veronese, industrial PhD student enrolled Uppsala University being part of the Marie Sklodowska Curie Awards #MSCA #EU funded #BACTIVE consortia. The overall goal is to reveal if the relatively unknown chemokine CXCL17 can be utilized when developing the next generation immunotherapies to reduce inflammation and fibrosis in the mucosa of the lungs and gastrointestinal tract. More specifically, the biological functions and biochemical properties of CXCL17 will be investigated, with specific focus on its potential anti-inflammatory and anti-microbial effects at different mucosal surfaces. We are all very exited and will support and follow your discoveries 😀 #ILP101 #lung #MDR #AMR #T2DM #ukraine

Ilya Pharma co-founders receives Hans Wigzells Research Foundations Scientific price of 100 000 USD. Press Release in Swedish: https://lnkd.in/dCmPnTca We are of course very honoured to receive this prize, Professor Hans Wigzell is one of the #pioneers in both #immunology and #microbiology and a national and international key opinion leader, investor, engine and facilitator for biotech and commecialization of new treatments that bring value for patients. The price reflects that we are on the right trajectory in the right time. Ilya Pharma is fighting disease by local instructions to immune cells and killing of multi drug resistant pathogens. -We would like to take this moment to thank all our collaborators, shareholders, stakeholders, research funding organizations, team members and patients,  says Evelina Vågesjö, CEO and Mia Phillipson BoD. #science #innovation #value #investment #AMR #MDR #ILP100 #ILP101 #nordicmade #EIC #EIThealth #vinnova #stuns #UU #SLU #diabetes #SAVI #ICI #colitis #ARDS #IPF #infection #NIH

Pod in Swedish with Professor Kristian Riesbeck about the spread of multi drug resistant bacteria in #Europe as a result of the war in Ukraine and current practices in health care. Kristian and colleagues have recently published in The Lancet Infectious Diseases on the status of resistance in the bacteria isolated from wounds in war victims (Ljungqvist et al., 2023) and bacteria with resistance to #ALL classes of existing antibiotics have been identified. Pod på svenska med Professor Kristian Riesbeck om spridningen av multirestsitenta bakterier till följd av kriget i Ukraina och dagen rutiner i sjukvården. Kristian med forskarkollegor har tidigare publicerat i Lancet Infectious Diseases status på resistensutveckling i bakterier (Ljungqvist et al., 2023) isolerade från sår från offer i Ukraina och rapporterat och bakterier med resistens mot #ALLA klasser av befintliga antibiotika har identifierats. #panresistance https://lnkd.in/dPkfCsWQ

Happening now at #IBD Nordic. Great work by Dr Yanhong Pang et al😀